Avagacestat
- Generic Name
- Avagacestat
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17ClF4N4O4S
- CAS Number
- 1146699-66-2
- Unique Ingredient Identifier
- TQ44WWY45Q
- Background
Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.
AstraZeneca and Lilly Form $500M Alliance to Develop Novel BACE Inhibitor for Alzheimer's Disease
• AstraZeneca and Eli Lilly have formed a strategic partnership to develop AZD3293, a promising oral BACE inhibitor for early Alzheimer's disease, with Lilly contributing $500 million in milestone payments.
• The collaboration combines AstraZeneca's innovative drug development capabilities with Lilly's 25-year expertise in Alzheimer's research, aiming to accelerate the development of a potential disease-modifying treatment.
• BACE inhibition represents a promising therapeutic approach targeting amyloid plaque formation, offering hope where previous Alzheimer's treatments have failed.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath